0.38
+0.0049(+1.29%)
Currency In USD
Address
505 Eagleview Boulevard
Exton, PA 19341
United States of America
Phone
(484) 348-1600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
January 25, 1996
| Name | Title | Pay | Year Born |
| Mr. John C. Taylor | Pres, Chief Executive Officer & Director | 444,062 | 1971 |
| Mr. John J. Kirby CPA | Chief Financial Officer | 813,071 | 1972 |
| Mr. Daniel Salain | Chief Operating Officer | 0 | 1968 |
| Mr. Andrew R. Jordan CPA, MBA | Chief Strategy Officer | 0 | 1948 |
| Dr. Carl Kraus M.D. | Chief Medical Officer | 0 | 1970 |
| Ms. Gwen Thomas | Associate Director of HR, Fin. & Admin. | 0 | N/A |
| Ms. Christina Amendola | Director of HR | 0 | N/A |
| Mr. Brian Jackey | Senior Vice President of Technical Operations | 0 | N/A |
| Ms. Deepa Nagpal | Global Head of Quality | 0 | N/A |
| Dr. Shah Rahimian M.D., Ph.D. | Medical Director & Global Clinical Lead for Oncology | 0 | N/A |
| Dr. Joanna Caroline Horobin Ch.B, M.B. | Advisor | 0 | 1955 |
| Mr. Louis J. Arcudi III, M.B.A., MBA | Adviser | 0 | 1961 |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.